Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder

Timothy E. Wilens, Jeffrey H. Newcorn, Christopher J. Kratochvil, Haitao Gao, Christine K. Thomason, Ann K. Rogers, Peter D. Feldman, Louise R. Levine

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. Results: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.

Original languageEnglish (US)
Pages (from-to)112-119
Number of pages8
JournalJournal of Pediatrics
Volume149
Issue number1
DOIs
StatePublished - Jul 1 2006

Fingerprint

Attention Deficit Disorder with Hyperactivity
Therapeutics
Drug Tolerance
Safety
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Pulse
Meta-Analysis
Atomoxetine Hydrochloride
Electrocardiography
Research Personnel
Blood Pressure
Weights and Measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., ... Levine, L. R. (2006). Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. Journal of Pediatrics, 149(1), 112-119. https://doi.org/10.1016/j.jpeds.2006.01.052

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. / Wilens, Timothy E.; Newcorn, Jeffrey H.; Kratochvil, Christopher J.; Gao, Haitao; Thomason, Christine K.; Rogers, Ann K.; Feldman, Peter D.; Levine, Louise R.

In: Journal of Pediatrics, Vol. 149, No. 1, 01.07.2006, p. 112-119.

Research output: Contribution to journalArticle

Wilens, TE, Newcorn, JH, Kratochvil, CJ, Gao, H, Thomason, CK, Rogers, AK, Feldman, PD & Levine, LR 2006, 'Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder', Journal of Pediatrics, vol. 149, no. 1, pp. 112-119. https://doi.org/10.1016/j.jpeds.2006.01.052
Wilens, Timothy E. ; Newcorn, Jeffrey H. ; Kratochvil, Christopher J. ; Gao, Haitao ; Thomason, Christine K. ; Rogers, Ann K. ; Feldman, Peter D. ; Levine, Louise R. / Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. In: Journal of Pediatrics. 2006 ; Vol. 149, No. 1. pp. 112-119.
@article{8e12c617f92a4258b6f6006d63fa285d,
title = "Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder",
abstract = "Objective: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. Results: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4{\%}) completed 3 months of acute treatment. A total of 259 subjects (48.4{\%}) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5{\%}) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2{\%}) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.",
author = "Wilens, {Timothy E.} and Newcorn, {Jeffrey H.} and Kratochvil, {Christopher J.} and Haitao Gao and Thomason, {Christine K.} and Rogers, {Ann K.} and Feldman, {Peter D.} and Levine, {Louise R.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.jpeds.2006.01.052",
language = "English (US)",
volume = "149",
pages = "112--119",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder

AU - Wilens, Timothy E.

AU - Newcorn, Jeffrey H.

AU - Kratochvil, Christopher J.

AU - Gao, Haitao

AU - Thomason, Christine K.

AU - Rogers, Ann K.

AU - Feldman, Peter D.

AU - Levine, Louise R.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Objective: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. Results: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.

AB - Objective: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. Results: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=33746154521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746154521&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2006.01.052

DO - 10.1016/j.jpeds.2006.01.052

M3 - Article

C2 - 16860138

AN - SCOPUS:33746154521

VL - 149

SP - 112

EP - 119

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -